PT  - JOURNAL ARTICLE
AU  - Gajendragadkar, PR
AU  - Von Ende, A
AU  - Murgia, F
AU  - Offer, A
AU  - Camm, CF
AU  - Wijesurendra, RS
AU  - Casadei, B
AU  - Hopewell, JC
TI  - Discrete mechanistic pathways underlying genetic predisposition to atrial fibrillation are associated with different intermediate cardiac phenotypes and risk of cardioembolic stroke
AID  - 10.1101/2024.07.10.24310244
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.10.24310244
4099  - http://medrxiv.org/content/early/2024/07/16/2024.07.10.24310244.short
4100  - http://medrxiv.org/content/early/2024/07/16/2024.07.10.24310244.full
AB  - Background Genome-wide association studies (GWAS) have clustered candidate genes associated with atrial fibrillation (AF) into biological pathways reflecting different pathophysiological mechanisms. We investigated whether these pathways associate with distinct intermediate phenotypes and confer differing risks of cardioembolic stroke.Methods Three distinct subsets of AF-associated genetic variants, each representing a different mechanistic pathway, i.e., the cardiac muscle function and integrity pathway (15 variants), the cardiac developmental pathway (25 variants), and the cardiac ion channels pathway (12 variants), were identified from a previous AF GWAS. Using genetic epidemiological methods and large-scale datasets such as UK Biobank, deCODE, and GIGASTROKE, we investigated the associations of these pathways with AF-related cardiac intermediate phenotypes, which included ECG parameters (∼16,500 ECGs), left atrial and ventricular size and function (∼36,000 cardiac MRI scans), and relevant plasma biomarkers (NT-proBNP, ∼70,000 samples; high-sensitivity troponin I and T, ∼87,000 samples), as well as with subtypes of ischaemic stroke (∼11,000 cases).Results Genetic variants representing distinct AF-related mechanistic pathways had significantly different effects on several AF-related phenotypes. In particular, the muscle pathway was associated with a longer PR interval (P for heterogeneity between pathways [Phet] = 1 × 10-10), lower LA emptying fraction (Phet = 5 × 10-5), and higher NT-proBNP (Phet = 2 × 10-3) per log-odds higher risk of AF compared to the developmental and ion channel pathways. By contrast, the ion channel pathway was associated with a lower risk of cardioembolic stroke (Phet = 0.04 in European, and 7 × 10-3 in multi-ancestry populations) compared to the other pathways.Conclusions Genetic variants representing specific mechanistic pathways for AF are associated with distinct intermediate cardiac phenotypes and a different risk of cardioembolic stroke. These findings provide a better understanding of the aetiological heterogeneity underlying the development of AF and its downstream impact on disease and may offer a route to more targeted treatment strategies.Competing Interest StatementPRG, AVE, CFC, FM, RSW, and JCH work at the Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, which receives research grants from industry that are governed by University of Oxford contracts that protect its independence, and has a staff policy of not taking personal payments from industry; further details can be found at https://www.ndph.ox.ac.uk/about/independence-of-research. BC is supported by a British Heart Foundation (BHF) personal chair; her research is funded by two BHF Programme Grants, the BHF Centre for Research Excellence and the NIHR Oxford Biomedical Research Centre. She also receives in-kind research support from iRhythm and Roche Diagnostics. JCH is supported by the British Heart Foundation; her research is funded by the BHF Centre for Research Excellence Oxford and the NIHR Oxford Biomedical Research Centre, and by grants from industry held in accordance with the policy detailed above, and the Nuffield Department of Population Health.Funding StatementThis work was supported by the British Heart Foundation (grant numbers FS/17/17/32438 [PRG, BC], FS/20/15/34920 [CFC, JCH], RG/16/12/3245 and CH/12/3/29609 [BC], and FS/14/55/30806 and CH/1996001/9454 [JCH]). The authors also acknowledge support from: the European Union (grant agreement 633196 - CATCH ME); BHF Centre for Research Excellence, Oxford, National Institute of Health Research (NIHR) Oxford Biomedical Research Centre, and Nuffield Department of Population Health, University of Oxford, UK. British Heart Foundation. The funders had no role in study design, data collection or analysis, preparation of the manuscript, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank data was used from the UK Biobank Resource under Application Number 14568. All procedures and data collection in UK Biobank were approved by the UK Biobank Research Ethics Committee (reference number 11/NW/0274) with participants providing full written informed consent for participation and subsequent use of their data for approved applications. Publicly available non-identifiable summary statistics were used in this study for which the multiple contributory studies to the various datasets had their own consent procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableData are available from UK Biobank (http://biobank.ndph.ox.ac.uk/showcase/) in accordance with their published data access procedures. All other data are publicly available or were obtained from corresponding authors of studies as detailed in the Methods section and Supplementary Table 5.